◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Otsuka Holdings Co., Ltd. (4578) EPS 2022–2025
DATA UPDATED 2026-10-02
Otsuka Holdings Co., Ltd. annual earnings per share (EPS) for fiscal 2025 was JPY 685.06, an increase of 8.1% from JPY 633.76 in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
4578 Annual EPS
| EPS (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|
| Diluted EPS | JPY 685M | JPY 634M | JPY 224M | JPY 247M |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
4578 Quarterly EPS
| EPS (quarterly) | 2026-03-31 | 2025-03-31 |
|---|
| Diluted EPS | JPY 186M | JPY 159M |
JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
EPS at Comparable Companies
- 4519 EPS — Chugai Pharmaceutical Co., Ltd.
- 4568 EPS — Daiichi Sankyo Company, Limited
- 4503 EPS — Astellas Pharma Inc.
- 4528 EPS — Ono Pharmaceutical Co., Ltd.
- 4536 EPS — Santen Pharmaceutical Co., Ltd.
- GLAXO EPS — GlaxoSmithKline Pharmaceuticals Limited
More 4578 metrics: Revenue · Gross Profit · Operating Income · Net Income · Free Cash Flow
All 4578 financial statements → Interactive 4578 charts →
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.